Toll Free: 1-888-928-9744

Anxiety Disorders - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 289 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anxiety Disorders - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Anxiety Disorders - Pipeline Review, H2 2015', provides an overview of the Anxiety Disorders's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Anxiety Disorders Overview 11 Therapeutics Development 12 Pipeline Products for Anxiety Disorders - Overview 12 Pipeline Products for Anxiety Disorders - Comparative Analysis 13 Anxiety Disorders - Therapeutics under Development by Companies 14 Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 19 Anxiety Disorders - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Anxiety Disorders - Products under Development by Companies 24 Anxiety Disorders - Products under Investigation by Universities/Institutes 30 Anxiety Disorders - Companies Involved in Therapeutics Development 32 AbbVie Inc. 32 Ache Laboratorios Farmaceuticos S/A 33 Adamed Sp. z o.o. 34 Addex Therapeutics Ltd 35 Avineuro Pharmaceuticals, Inc. 36 Azevan Pharmaceuticals, Inc. 37 Bionomics Limited 38 Boehringer Ingelheim GmbH 39 C4X Discovery Limited 40 Catalyst Pharmaceutical Partners, Inc. 41 Edgemont Pharmaceuticals, LLC 42 Eisai Co., Ltd. 43 Eli Lilly and Company 44 F. Hoffmann-La Roche Ltd. 45 Gabather AB 46 GW Pharmaceuticals Plc 47 H. Lundbeck A/S 48 HolsboerMaschmeyer NeuroChemie GmbH 49 Humanetics Corporation 50 Intra-Cellular Therapies, Inc. 51 Johnson & Johnson 52 Marinus Pharmaceuticals, Inc. 53 Merz Pharma GmbH & Co. KgaA 54 MI.TO. Technology S.r.L. 55 Neuralstem, Inc. 56 Neurocrine Biosciences, Inc. 57 NeuroNascent, Inc. 58 Newron Pharmaceuticals S.p.A. 59 Nippon Chemiphar Co., Ltd. 60 Novartis AG 61 Omeros Corporation 62 Otsuka Holdings Co., Ltd. 63 Pherin Pharmaceuticals, Inc. 64 Polleo Pharma Limited 65 Protagenic Therapeutics Inc. 66 Rottapharm SpA 67 Sellas Inc. 68 Suda Ltd 69 Sumitomo Dainippon Pharma Co., Ltd. 70 Synchroneuron Inc. 71 Tonix Pharmaceuticals Holding Corp. 72 Trevena, Inc. 73 Vanda Pharmaceuticals Inc. 74 Anxiety Disorders - Therapeutics Assessment 75 Assessment by Monotherapy Products 75 Assessment by Target 76 Assessment by Mechanism of Action 80 Assessment by Route of Administration 84 Assessment by Molecule Type 86 Drug Profiles 88 18-MC - Drug Profile 88 acamprosate calcium SR - Drug Profile 89 ACH-36 - Drug Profile 91 ADN-2013 - Drug Profile 92 ADX-71441 - Drug Profile 93 ADX-71743 - Drug Profile 94 ADX-88178 - Drug Profile 95 alprazolam - Drug Profile 96 AM-3506 - Drug Profile 97 AVN-101 - Drug Profile 98 AVN-628 - Drug Profile 99 BCA-909 - Drug Profile 100 BHV-0223 - Drug Profile 101 BNC-210 - Drug Profile 103 brexpiprazole - Drug Profile 105 CPP-115 - Drug Profile 108 CR-5542 Series - Drug Profile 110 dipraglurant IR - Drug Profile 111 Drug for Post-Traumatic Stress Disorders - Drug Profile 112 Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 113 Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 114 Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 115 E-2508 - Drug Profile 116 evenamide - Drug Profile 117 fluvoxamine maleate - Drug Profile 118 Gaaba-001 - Drug Profile 119 ganaxolone - Drug Profile 120 HL-9001 - Drug Profile 122 IC-87201 - Drug Profile 123 iloperidone - Drug Profile 124 ITI-007 - Drug Profile 126 JNJ-42165279 - Drug Profile 128 lorazepam ER - Drug Profile 129 LSN-2535717 - Drug Profile 130 LY-2607540 - Drug Profile 131 mavoglurant - Drug Profile 132 midazolam hydrochloride - Drug Profile 134 MRZ-8676 - Drug Profile 135 nabiximols - Drug Profile 136 NB-51R1 - Drug Profile 139 NEO-1940 - Drug Profile 140 NNI-351 - Drug Profile 141 NSI-189 - Drug Profile 142 OMS-527 - Drug Profile 144 Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 145 PH-94B - Drug Profile 146 PT-00114 - Drug Profile 148 PT-00121 - Drug Profile 149 PT-00211 - Drug Profile 150 PT-00411 - Drug Profile 151 RO-646198 - Drug Profile 152 Rycal - Drug Profile 153 S-107 - Drug Profile 154 SCT-66 - Drug Profile 155 Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile 156 Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile 157 Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 158 Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 159 Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 160 Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 161 Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 162 Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 163 Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile 164 Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 165 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 166 Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 168 Small Molecules to Agonize D2 and Inhibit MAO for Depression and Anxiety - Drug Profile 169 Small Molecules to Agonize Delta Opioid Receptor for Anxiety and Depression - Drug Profile 170 Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 171 Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 172 Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile 173 Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 174 Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile 175 Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 176 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 177 Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 178 Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 179 Small Molecules to Modulate Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 180 Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile 181 SRX-246 - Drug Profile 182 STX - Drug Profile 184 tedatioxetine hydrobromide - Drug Profile 185 TNX-102 - Drug Profile 187 TPI-136117 - Drug Profile 189 TRV-250 - Drug Profile 190 UCM-765 - Drug Profile 192 Vaccine for CNS Disorders - Drug Profile 193 VAD-1 - Drug Profile 194 VAD-2 - Drug Profile 195 verucerfont - Drug Profile 196 vigabatrin - Drug Profile 198 vortioxetine hydrobromide - Drug Profile 201 VU-0431316 - Drug Profile 204 ZL-006 - Drug Profile 205 zolpidem tartrate - Drug Profile 206 Anxiety Disorders - Recent Pipeline Updates 207 Anxiety Disorders - Dormant Projects 256 Anxiety Disorders - Discontinued Products 270 Anxiety Disorders - Product Development Milestones 275 Featured News & Press Releases 275 Appendix 282 Methodology 282 Coverage 282 Secondary Research 282 Primary Research 282 Expert Panel Validation 282 Contact Us 282 Disclaimer 283
List of Tables
Number of Products under Development for Anxiety Disorders, H2 2015 18 Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2015 19 Number of Products under Development by Companies, H2 2015 21 Number of Products under Development by Companies, H2 2015 (Contd..1) 22 Number of Products under Development by Companies, H2 2015 (Contd..2) 23 Number of Products under Development by Companies, H2 2015 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2015 25 Comparative Analysis by Late Stage Development, H2 2015 26 Comparative Analysis by Clinical Stage Development, H2 2015 27 Comparative Analysis by Early Stage Development, H2 2015 28 Comparative Analysis by Unknown Stage Development, H2 2015 29 Products under Development by Companies, H2 2015 30 Products under Development by Companies, H2 2015 (Contd..1) 31 Products under Development by Companies, H2 2015 (Contd..2) 32 Products under Development by Companies, H2 2015 (Contd..3) 33 Products under Development by Companies, H2 2015 (Contd..4) 34 Products under Development by Companies, H2 2015 (Contd..5) 35 Products under Investigation by Universities/Institutes, H2 2015 36 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 37 Anxiety Disorders - Pipeline by AbbVie Inc., H2 2015 38 Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 39 Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2015 40 Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2015 41 Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2015 42 Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015 43 Anxiety Disorders - Pipeline by Bionomics Limited, H2 2015 44 Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2015 45 Anxiety Disorders - Pipeline by C4X Discovery Limited, H2 2015 46 Anxiety Disorders - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 47 Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2015 48 Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2015 49 Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2015 50 Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 51 Anxiety Disorders - Pipeline by Gabather AB, H2 2015 52 Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H2 2015 53 Anxiety Disorders - Pipeline by H. Lundbeck A/S, H2 2015 54 Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2015 55 Anxiety Disorders - Pipeline by Humanetics Corporation, H2 2015 56 Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 57 Anxiety Disorders - Pipeline by Johnson & Johnson, H2 2015 58 Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015 59 Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015 60 Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H2 2015 61 Anxiety Disorders - Pipeline by Neuralstem, Inc., H2 2015 62 Anxiety Disorders - Pipeline by Neurocrine Biosciences, Inc., H2 2015 63 Anxiety Disorders - Pipeline by NeuroNascent, Inc., H2 2015 64 Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2015 65 Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 66 Anxiety Disorders - Pipeline by Novartis AG, H2 2015 67 Anxiety Disorders - Pipeline by Omeros Corporation, H2 2015 68 Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 69 Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015 70 Anxiety Disorders - Pipeline by Polleo Pharma Limited, H2 2015 71 Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H2 2015 72 Anxiety Disorders - Pipeline by Rottapharm SpA, H2 2015 73 Anxiety Disorders - Pipeline by Sellas Inc., H2 2015 74 Anxiety Disorders - Pipeline by Suda Ltd, H2 2015 75 Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 76 Anxiety Disorders - Pipeline by Synchroneuron Inc., H2 2015 77 Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015 78 Anxiety Disorders - Pipeline by Trevena, Inc., H2 2015 79 Anxiety Disorders - Pipeline by Vanda Pharmaceuticals Inc., H2 2015 80 Assessment by Monotherapy Products, H2 2015 81 Number of Products by Stage and Target, H2 2015 83 Number of Products by Stage and Mechanism of Action, H2 2015 87 Number of Products by Stage and Route of Administration, H2 2015 91 Number of Products by Stage and Molecule Type, H2 2015 93 Anxiety Disorders Therapeutics - Recent Pipeline Updates, H2 2015 213 Anxiety Disorders - Dormant Projects, H2 2015 262 Anxiety Disorders - Dormant Projects (Contd..1), H2 2015 263 Anxiety Disorders - Dormant Projects (Contd..2), H2 2015 264 Anxiety Disorders - Dormant Projects (Contd..3), H2 2015 265 Anxiety Disorders - Dormant Projects (Contd..4), H2 2015 266 Anxiety Disorders - Dormant Projects (Contd..5), H2 2015 267 Anxiety Disorders - Dormant Projects (Contd..6), H2 2015 268 Anxiety Disorders - Dormant Projects (Contd..7), H2 2015 269 Anxiety Disorders - Dormant Projects (Contd..8), H2 2015 270 Anxiety Disorders - Dormant Projects (Contd..9), H2 2015 271 Anxiety Disorders - Dormant Projects (Contd..10), H2 2015 272 Anxiety Disorders - Dormant Projects (Contd..11), H2 2015 273 Anxiety Disorders - Dormant Projects (Contd..12), H2 2015 274 Anxiety Disorders - Dormant Projects (Contd..13), H2 2015 275 Anxiety Disorders - Discontinued Products, H2 2015 276 Anxiety Disorders - Discontinued Products (Contd..1), H2 2015 277 Anxiety Disorders - Discontinued Products (Contd..2), H2 2015 278 Anxiety Disorders - Discontinued Products (Contd..3), H2 2015 279 Anxiety Disorders - Discontinued Products (Contd..4), H2 2015 280



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify